MarketFriction

SMS Pharmaceuticals Ltd

NSE SMSPHARMA · BSE 532815 · Pharmaceuticals
₹471.30 -1.11%
NSE close2026-10-01
52 week range242.25 - 494.45
Market cap₹4,494 Cr.
P/E43.9
Price band 20% Delivery 42.6%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales167161246164197173248196242210238207
Expenses139132212131165140207157194167198166
Operating Profit282934343133413948444041
OPM %17%18%14%20%16%19%16%20%20%21%17%20%
Other Income112112111432
Interest666554566656
Depreciation88889991010101010
Profit before tax151722222022292434312727
Tax %21%26%26%25%29%24%30%23%26%26%23%26%
Net Profit121117161418202025233321
EPS in Rs1.381.362.041.951.662.152.292.312.702.513.492.23
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales611438463465412563520522709783887898
Expenses522363369375332442405467593644716725
Operating Profit897593908012111555117139171173
OPM %15%17%20%19%19%22%22%10%16%18%19%19%
Other Income412353554689
Interest171615121211192224192323
Depreciation191920192222323232344040
Profit before tax5642606251916856692117119
Tax %26%14%33%34%36%33%1%28%26%27%25%
Net Profit41283240326362-75069102102
EPS in Rs4.833.363.754.733.737.387.35-0.835.887.8010.8910.93
Dividend Payout %4%6%7%5%7%4%4%-36%7%5%4%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth4%10%19%10%
Compounded Profit Growth10%10%155%40%
Stock Price CAGR18%25%56%96%
Return on Equity11%10%12%14%
Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital1088888888899
Reserves182285246276313340402462452528631776
Borrowings73204149146144157255263254281311365
Other Liabilities64158897293103147126165217202212
Total Liabilities3296564935035596088128608801,0341,1531,362
Fixed Assets69370290279281280457438412437533534
CWIP1513881842711333035122
Investments02129282726272211111226
Other Assets245252166187232259321389424556573681
Total Assets3296564935035596088128608801,0341,1531,362
Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity146173325040904522508259
Cash from Investing Activity-32-97-39-17-35-43-152-27-30-52-123-131
Cash from Financing Activity10727-33-15-13-292-12-32314776
Net Cash Flow89-9102-5316-392954
Free Cash Flow-5-27502315-3-6118-7-2-42-71
CFO/OP42%93%110%46%70%65%88%52%50%56%73%49%
Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days114361819204368341041229589
Inventory Days165106114135170191148333243201238260
Days Payable72798249596670971171309589
Cash Conversion Cycle2066350105131169146270230192237260
Working Capital Days16919-22739574894104858898
ROCE %13%18%17%13%17%13%4%12%13%13%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters64.32%64.32%64.67%64.67%64.67%64.67%66.27%66.27%68.07%68.07%68.07%68.07%
FIIs0.60%0.59%0.17%0.18%0.52%0.31%0.08%0.03%0.28%0.04%0.31%0.65%
DIIs0.00%0.00%1.98%2.13%2.55%2.55%2.43%3.03%2.88%3.21%3.02%2.83%
Public35.07%35.10%33.18%33.03%32.27%32.47%31.23%30.68%28.77%28.69%28.60%28.45%
No. of Shareholders25,24625,34130,14031,78033,13634,97335,33233,65234,15734,37832,39731,489

Fundamentals

Market Cap₹ 4,494 Cr.
Current Price₹ 479
Stock P/E43.9
Book Value₹ 83.9
ROCE13.3 %
ROE14.3 %
Dividend Yield0.08 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)10%
Compounded Profit Growth (TTM)40%
Consolidated figures.
Valuation
Market capRs 4,418 Cr
Enterprise valueRs 4,737 Cr
P/E (TTM)43.14x
Price to book5.62x
Price to sales4.92x
EV / EBITDA25.97x
EV / EBIT33.30x
EV / sales5.28x
Price to cash flow74.60x
Earnings yield2.32%
Dividend yield0.08%
P/E, 3-year average28.78x
P/B, 3-year average2.88x
P/E, 5-year average23.43x
P/B, 5-year average2.13x
Profitability
Operating margin (excl. other income)19.31%
Operating margin (incl. other income)20.26%
EBITDA margin20.31%
Pre-tax margin13.31%
Net profit margin11.41%
Net margin, latest quarter10.10%
ROE14.31%
ROCE13.30%
ROA8.11%
ROE, 3-year average12.02%
ROCE, 3-year average12.52%
ROA, 3-year average6.55%
ROE, 5-year average9.74%
ROCE, 5-year average10.77%
ROA, 5-year average5.25%
ROIC (approx.)9.71%
Tax rate24.55%
Other income / net worth1.06%
Growth
Sales growth (latest year)13.30%
Profit growth (latest year)47.51%
Sales CAGR, 3 years19.32%
Sales CAGR, 5 years9.51%
Profit CAGR, 5 years10.28%
Sales growth QoQ-13.02%
Profit growth QoQ-36.07%
Sales growth YoY (latest quarter)5.56%
Profit growth YoY (latest quarter)2.05%
Per share
EPS (TTM)Rs 10.92
EPS (latest quarter)Rs 2.23
EPS, 3-year averageRs 6.84
EPS, 5-year averageRs 5.05
Book value per shareRs 83.83
Sales per shareRs 95.78
Cash flow per shareRs 6.32
Free cash flow per shareRs -7.57
Dividend per share, 3-year averageRs 0.40
Dividend per share, 5-year averageRs 0.35
Dividends
Dividend payout3.68%
Dividend payout, 3-year average5.20%
Dividend payout, 5-year average4.92%
Efficiency
Asset turnover0.65x
Fixed asset turnover1.66x
Inventory turnover1.40x
Inventory days260 days
Debtor days89 days
Debtors turnover4.11x
Creditor days89 days
Cash conversion cycle260 days
Working capital days98 days
Leverage
Total debtRs 365 Cr
Cash and bankRs 46 Cr
Net debtRs 319 Cr
Debt to equity0.46x
Net debt / EBITDA1.75x
Interest coverage6.25x
Current ratio (filing 2026-03-31)1.81x
Quick ratio (filing 2026-03-31)0.81x
Trade payables (filing 2026-03-31)Rs 120 Cr
Owners' fund to total sources57.68%
Debt to assets26.79%
Cash flow
Cash from Operating Activity (latest year)Rs 59 Cr
Cash from Investing Activity (latest year)Rs -131 Cr
Cash from Financing Activity (latest year)Rs 76 Cr
Net Cash Flow (latest year)Rs 4 Cr
Free cash flow (latest year)Rs -71 Cr
FCFE (approx.: FCF + change in debt)Rs -17 Cr
Cash from ops / profit, 5 years0.93x
Sales to cash flow14.98x
Statement figures
Net sales (TTM)Rs 898 Cr
Net sales (latest year)Rs 887 Cr
Sales (latest quarter)Rs 207 Cr
Operating profit excl. other income (latest year)Rs 171 Cr
Operating profit (latest quarter)Rs 41 Cr
Other income (TTM)Rs 9 Cr
EBITDA (TTM)Rs 182 Cr
PBDT (TTM)Rs 160 Cr
Profit before tax (TTM)Rs 119 Cr
Tax (latest year)Rs 29 Cr
Net profit (TTM)Rs 102 Cr
Net profit (latest year)Rs 102 Cr
Net profit (latest quarter)Rs 21 Cr
Depreciation (TTM)Rs 40 Cr
Depreciation (latest quarter)Rs 10 Cr
Interest (TTM)Rs 23 Cr
Cost of goods sold (latest year)Rs 493 Cr
Total expenditure (latest year)Rs 716 Cr
Total income (latest year)Rs 895 Cr
Share capitalRs 9 Cr
ReservesRs 776 Cr
Shareholders' fundsRs 786 Cr
Total assetsRs 1,362 Cr
Net blockRs 534 Cr
Capital work in progressRs 122 Cr
InvestmentsRs 26 Cr
ReceivablesRs 216 Cr
InventoryRs 351 Cr
Other liabilitiesRs 212 Cr
Shares outstanding (crore)9.37
Ownership
Promoter holding68.07% (+1.80 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 40.8 is at the 90th percentile of its own 8.4-year range (median 23.3, low 6.0, high 62.4).
P/B 5.32 is at the 95th percentile (median 2.58).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodSMSPHARMANifty 50Difference
1 week-0.6%-2.8% +2.2 pts
1 month+28.0%-6.8% +34.8 pts
3 months+11.8%-7.6% +19.4 pts
6 months+25.7%+0.4% +25.3 pts
1 year+74.1%-9.9% +84.1 pts
2 years+25.1%-13.6% +38.6 pts
3 years+274.5%+14.2% +260.3 pts
5 years+210.0%+27.9% +182.1 pts
3 mutual fund schemes hold about ₹57 Cr. Over three months 0 bought more and 3 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Quant Healthcare Fund6.71%29 -26%
Quant Small Cap Fund0.08%28 -70%
Bandhan BSE Healthcare Index Fund0.07%0 -23%

Red flags

F-score 5 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹207 Cr +5.6% vs Jun 2025. Net profit ₹21 Cr +5.0%.
Against our estimate for Jun 2026: sales -2.8%, profit -7.4% in line. Our estimate for Sep 2026: sales Rs 244 Cr, profit Rs 26 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-09-22Dividend - Re 0.40 Per Share
2025-09-22Dividend - Re 0.40 Per Share
2024-09-23Dividend - Rs 0.40 Per Share
2024-09-23Annual General Meeting
2023-09-22Dividend - Re 0.30 Per Share
2023-09-22Annual General Meeting
2022-09-22Dividend - Re 0.30 Per Share
2022-09-22Annual General Meeting
2021-09-22 Annual General Meeting/ Dividend Rs 0.30 Per Share
2020-09-17 Annual General Meeting
2020-03-26 Interim Dividend - Rs 0.25 Per Share
2019-09-19 Dividend - Rs 0.25 Per Share
2018-09-11 Annual General Meeting/Dividend Re 0.25 Per Share
2017-09-20 Annual General Meeting/Dividend - Rs 0.20 Per Share
2017-06-22 Scheme Of Arrangement
2016-09-22 Dividend Re 0.20 Per Share
2015-12-17 Face Value Split (Sub-Division) - From Rs 10/- Per Share To Re 1/- Per Share0.1000
2015-09-22 Annual General Meeting/ Dividend - Rs 2/- Per Share
2014-09-23Annual General Meeting And Dividend Rs.2/- Per Share
2013-09-23Annual General Meeting / Dividend - Rs 2 Per Share
2012-09-20Annual General Meeting
2011-09-22Annual General Meeting/Dividend Rs 1.50 Per Share
2010-09-23Annual General Meeting And Dividend Re.1/- Per Share
2009-09-23Agm/Div-Rs.2/- Per Share
2008-12-23Agm/Dividend - 20%
2007-09-21Agm/Dividend-20%
DateTypeWhat it says
2026-09-30Shareholder meetingVoting results.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 25perc in previous 1 month

Quick answers

What is the market cap of SMS Pharmaceuticals Ltd?

SMS Pharmaceuticals Ltd (SMSPHARMA) has a market capitalisation of Rs 4,494 Cr. at the 2026-10-01 close.

What is the P/E ratio of SMS Pharmaceuticals Ltd?

SMS Pharmaceuticals Ltd trades at a P/E of 43.9 on trailing twelve-month profit, at the 2026-10-01 close.

What were SMS Pharmaceuticals Ltd's latest quarterly results?

In the Jun 2026 quarter, SMS Pharmaceuticals Ltd sales was Rs 207 Cr (+5.6% vs Jun 2025) and net profit was Rs 21 Cr.

What is the 52-week high and low of SMS Pharmaceuticals Ltd?

The 52-week high is Rs 494.45 and the 52-week low is Rs 242.25.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03